The invention is concerned with a pharmaceutical and industrial iodophor preparation, its synthesis and potential applications. The compound has predictable antimicrobial activities. Furthermore, this iodophor is much more stable in the presence of organic material than traditional iodophors. The compositions release free iodine when in solution, which provides the antimicrobial activity.

The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Pharmaceutical compositions comprising 4-hydroxy tamoxifen in an amount of 0.105-0.950% by weight effectively deliver the 4-hydroxy tamoxifen. Such compositions, including gels, can treat or prevent benign breast disease, scarring or a keloid, gynecomastia, breast cancer, mastalgia, or a condition involving dense breast tissue.

Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

A teat protective pack material for coating teats of lactating livestock to prevent mastitis is disclosed, the teat protective pack material including a polymer latex and a coagulant for coagulating the polymer latex to form a film. The teat protective pack material optionally includes a surfactant, a mold-releasing agent, a water-soluble polymer, water and/or a water-soluble solvent, an antifreezing agent, etc. if required. The teat protective pack material, may have excellent adhesiveness, elasticity, abrasion resistance, durability, aging resistance, oil resistance, weatherability, breast shape followability, etc. The teat protective pack material may be capable of immediately coating the whole teat and thus preventing adhesion of teat packs adjacent to each other, and, when milking again or in case of emergency, may be able to be quickly removed without using any additional facility, material, etc.

A safety valve arrangement and method, having an upstream block valve, a downstream block valve, and a pressure monitored galley between the upstream valve and the downstream valve.

A method of treating or preventing mastitis in a bovine animal comprising administering to the animal a therapeutically effective amount of particular microbes thereby treating or preventing mastitis in the animal.

Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to the hydrophobic active agent, and a silicone tubing having a wall permeable to the hydrophobic active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the silicone tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver the hydrophobic active agent to the target tissue, and kits that find use in performing the present method.

An intramammary syringe contains a seal formulation for forming a physical barrier in the teat canal of a non-human animal. The syringe contains a reduced volume of from 0.25 ml to 2.0 ml of the seal formulation. The problem of ascending sealant during the dry period is solved.

A novel standardized liquid propolis extract and pharmaceutical formulation based on said extract, as well as their manufacturing methods and uses, are provided. The liquid extract is produced by extraction of crude propolis with an extraction solvent based on a mixture of PEG 200-600 (96.5-99.9% w/w) and lecithins (0.1-3.5% w/w). The extract is characterized with standardized content of p-coumaric acid (1), trans-ferulic acid (2), caffeic acid (3), and CAPE (4). It is used as an active ingredient in manufacturing of pharmaceutical, cosmetic, veterinary, agrochemical or functional food products. The pharmaceutical formulation according to the invention consists of 5-95% w/w of the said propolis extract and up to 100% excipients required for preparation of various dosage forms. It is used for treatment of diseases and conditions in humans and animals such as: inflammatory diseases, bacterial and fungal infections, viral, autoimmune and cancer diseases, and for the treatment of burns and wound healing.